medwireNews: The Rho-associated kinase inhibitor fasudil as an adjunct to riluzole is well tolerated for the treatment of patients with amyotrophic lateral sclerosis, indicate phase 2 findings from the ROCK-ALS study.
Read the full story on the L’Institut Servier website
Image credit: © herraez / stock.adobe.com
